/

Baxter International Inc.

BAX US

BAX USBaxter International Inc.

United States Composite

40.93

USD

-0.09

(-0.22%)

5.24EPS Dil.

7.80P/E

20.78BMarket Cap

2.83%Div. Yield

Next Earnings

April 25

Ex-Dividend Date

February 29

Dividend Date

April 1

Held by Insiders

0.39%

Held by Institutions

92.75%

Short % of Float

1.60%

YTD Yield

-11.09%

3Y Yield

-54.02%

5Y Yield

-47.02%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

2,177

2,426

2,796

LT Borrowings

14,306

14,067

11,130

LT Finance Leases

438

436

438

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

506

507

508

Market Capitalization

23,070

19,145

19,625

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

8,205

12,034

9,600

Cash, Cash Equivalents & STI

1,722

5,788

3,194

Accounts Receivable, Net

2,495

2,512

2,690

Inventories

2,897

2,873

2,824

Total Current Liabilities

5,765

6,209

6,503

Payables & Accruals

3,518

3,783

2,764

ST Debt

2,177

2,426

2,796

Deferred Revenue

- -

148

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

4.85%

6.14%

2.12%

Net Income, GAAP

-6.26%

-101.46%

-209.17%

Free Cash Flow

1.09%

6.33%

74.96%

Total Cash Common Dividend

0.32%

9.35%

2.27%

Total Equity

1.83%

4.74%

43.65%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2,946

3,098

3,226

3,514

12,146

2022

3,707

3,594

3,609

3,887

14,506

2023

3,649

3,707

3,708

3,885

14,813

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.59

0.90

0.48

2.56

2022

0.14

0.50

-5.83

0.36

-4.83

2023

0.09

-0.28

4.95

0.48

5.25

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

0.25

0.28

1.06

2022

0.28

0.29

1.14

2023

0.29

1.16

Company Description

CEO: Mr. Jose E. Almeida
Full Time Employees: 60,000
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: One Baxter Parkway Deerfield IL United States 60015
IPO Date: Oct 27, 1981
CIK: 0000010456
Website: www.baxter.com
Business: Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Company News

Yahoo
23 days ago
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
Zacks
23 days ago
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
Tipranks
23 days ago
Baxter’s Novum IQ Launch: A Hold Rating Amid Competitive Challenges and Market Opportunities
Tipranks
23 days ago
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
Yahoo
24 days ago
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Yahoo
a month ago
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Yahoo
a month ago
Should You Hold Baxter International (BAX)?
Medtechdive
2 months ago
Baxter to close Massachusetts site, lay off 59 people
Yahoo
2 months ago
Insider Sell: EVP, Chief HR Officer Jeanne Mason Sells 64,488 Shares of Baxter International ...
Reuters
2 months ago
Dialysis firms gain as Ozempic kidney trial data disappoints
Tipranks
2 months ago
Baxter International Hold Rating: Assessing Kidney Care Asset Sale Versus Spin-Off

Company Description

CEO: Mr. Jose E. Almeida
Full Time Employees: 60,000
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: One Baxter Parkway Deerfield IL United States 60015
IPO Date: Oct 27, 1981
CIK: 0000010456
Website: www.baxter.com
Business: Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Company News

Yahoo
23 days ago
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
Zacks
23 days ago
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
Tipranks
23 days ago
Baxter’s Novum IQ Launch: A Hold Rating Amid Competitive Challenges and Market Opportunities
Tipranks
23 days ago
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
Yahoo
24 days ago
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Yahoo
a month ago
Baxter to Host Annual Meeting of Stockholders in Virtual Format
Yahoo
a month ago
Should You Hold Baxter International (BAX)?
Medtechdive
2 months ago
Baxter to close Massachusetts site, lay off 59 people
Yahoo
2 months ago
Insider Sell: EVP, Chief HR Officer Jeanne Mason Sells 64,488 Shares of Baxter International ...
Reuters
2 months ago
Dialysis firms gain as Ozempic kidney trial data disappoints
Tipranks
2 months ago
Baxter International Hold Rating: Assessing Kidney Care Asset Sale Versus Spin-Off